Suppr超能文献

P-糖蛋白的免疫组化定位及多药耐药-1基因在人胰腺癌中的表达:与较好预后指标的相关性

Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis.

作者信息

Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K, Manabe T, Imamura M, Hiai H, Fukumoto M

机构信息

Department of Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Jpn J Cancer Res. 1996 Jun;87(6):641-9. doi: 10.1111/j.1349-7006.1996.tb00271.x.

Abstract

We investigated immunohistochemical localization of P-glycoprotein (P-gp) on paraffin-embedded sections from 103 cases of previously untreated pancreatic tumors and also analyzed multidrug resistance-1 (MDR1) gene expression by polymerase chain reaction after reverse transcription in 35 cases. High positive staining for P-gp was observed in 72.8% of pancreatic tumors and in 73.2% of ductal adenocarcinoma. In ductal adenocarcinoma, immunoreactivity of P-gp was inversely correlated with biological aggressiveness of tumors determined by histologic grading (P<0.01), tumor size (P < 0.01), retroperitoneal invasion (P < 0.01) and portal invasion (P < 0.05). Expression of the MDR1 gene was detected in all the pancreatic tumors examined and was significantly higher than that in normal pancreas (P < 0.05). The levels of MDR1 mRNA showed a moderate correlation with those of P-gp (r=0.62, P<0.0001). Higher expression levels of MDR1/P-gp significantly correlated with better prognosis of patients with ductal carcinoma (P < 0.05). Among patients with ductal carcinoma, the high staining group for P-gp revealed a 3.5-fold better prognosis compared with the low staining group (HR=3.47, 95% CI=1.62, 7.45; P=0.0016). In conclusion, MDR1 gene/P-gp expression in pancreatic cancer without chemotherapy inversely correlates with biological aggressiveness and is an independent indicator of favorable prognosis.

摘要

我们研究了103例未经治疗的胰腺肿瘤石蜡包埋切片上P-糖蛋白(P-gp)的免疫组化定位,并对35例进行了逆转录后聚合酶链反应分析多药耐药1(MDR1)基因表达。在72.8%的胰腺肿瘤和73.2%的导管腺癌中观察到P-gp高阳性染色。在导管腺癌中,P-gp的免疫反应性与组织学分级(P<0.01)、肿瘤大小(P<0.01)、腹膜后侵犯(P<0.01)和门静脉侵犯(P<0.05)所确定的肿瘤生物学侵袭性呈负相关。在所检测的所有胰腺肿瘤中均检测到MDR1基因表达,且显著高于正常胰腺(P<0.05)。MDR1 mRNA水平与P-gp水平呈中度相关(r=0.62,P<0.0001)。MDR1/P-gp的较高表达水平与导管癌患者的较好预后显著相关(P<0.05)。在导管癌患者中,P-gp高染色组的预后比低染色组好3.5倍(HR=3.47,95%CI=1.62,7.45;P=0.0016)。总之,未经化疗的胰腺癌中MDR1基因/P-gp表达与生物学侵袭性呈负相关,是预后良好的独立指标。

相似文献

3
Determining MDR1/P-glycoprotein expression in breast cancer.检测乳腺癌中多药耐药蛋白1/ P-糖蛋白的表达
Int J Cancer. 2001 Jul 1;93(1):114-22. doi: 10.1002/1097-0215(20010701)93:1<114::aid-ijc1309>3.0.co;2-j.
4
Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer.
Pancreas. 2000 Oct;21(3):240-7. doi: 10.1097/00006676-200010000-00004.
6
Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.鼻T细胞淋巴瘤细胞中P-糖蛋白/MDR1的频繁表达。
Cancer. 1995 Dec 1;76(11):2351-6. doi: 10.1002/1097-0142(19951201)76:11<2351::aid-cncr2820761125>3.0.co;2-1.
10
mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy.
Breast Cancer Res Treat. 1997 Aug;45(1):63-74. doi: 10.1023/a:1005824704740.

引用本文的文献

10
Gene therapy in pancreatic cancer.胰腺癌的基因治疗。
World J Gastroenterol. 2014 Oct 7;20(37):13343-68. doi: 10.3748/wjg.v20.i37.13343.

本文引用的文献

1
MDR1 gene expression and its clinical relevance in primary gastric carcinomas.多药耐药基因1(MDR1)在原发性胃癌中的表达及其临床意义
Cancer. 1993 Feb 1;71(3):667-71. doi: 10.1002/1097-0142(19930201)71:3<667::aid-cncr2820710303>3.0.co;2-6.
2
Reliability of pancreatic cancer staging classifications.胰腺癌分期分类的可靠性。
Int J Pancreatol. 1994 Feb;15(1):13-8. doi: 10.1007/BF02924383.
10
The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein.负责多药耐药性的mdr1基因编码P-糖蛋白。
Biochem Biophys Res Commun. 1986 Dec 30;141(3):956-62. doi: 10.1016/s0006-291x(86)80136-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验